Regarding “Multidisciplinary approach in the management of a giant arteriovenous malformation in the right axillary region”  by Lee, Byung-Boong & Laredo, James
ings that diabetes appears to be a negative prognosticator when
percutaneous superficial femoral artery interventions are examined
and that use of an additional adjunctive modality does not correct
the underlying biology. Lenti et al1 have shown similar primary
patency rates as Meerwaldt et al but did find that critical ischemia
was associated with poorer outcomes.
In our article, we categorized our patient population into
claudicant and critical limb cohorts to avoid the confusion in the
data set presented by Meerwaldt et al. Their report is of a hetero-
geneous population of patients with claudication and critical isch-
emia and as such cannot be compared directly with our data set or
with that of Lenti et al. It is vital not to confuse the subject with
mixed populations because this leads to misinterpretations. We
would have also been interested to know if there was a correlation
with advanced glycation end products (AGE) and outcomes in this
population and if their limb salvage rates matched our findings in
the diabetic patients with critical ischemia. We agree with the
authors that a more refined classification of diabetes is important.
The need for insulin therapy is a significant differentiation factor in
the adult population.
Unfortunately, AGE measurements are not standard clinical
practice, and thus, we used a system that would be applicable to all
practitioners in the field. Meerwaldt et al did not show any corre-
lation with AGE levels and outcomes and did not separate out their
population into insulin-dependent and non-insulin-dependent di-
abetes mellitus. However, there is convincing evidence in vitro and
in vivo of the impact of AGE on vessel wall biology. Up-regulation
of AGE receptor and increased expression of AGEs occur in the
vessel wall after injury in animals.2,3 Choi et al4 have shown in
diabetic patients receiving coronary stenting that an elevated level
of serumAGEs is an independent risk factor for the development of
angiographic restenosis in the coronary circulation. AGEs are
associated with enhanced inflammation, and other markers of
inflammation such as C-reactive protein have been shown to be
associated with decreased patency of SFA interventions.5,6
Whether the AGE data from coronary stenting is referable to the
angioplasty of the superficial femoral artery is questionable.
The authors raise a valid point that severity of foot ulceration
and neuropathy do significantly influence the outcomes of foot
salvage in diabetic patients with tissue loss. In a subgroup analysis,
we did demonstrate that the presence of tissue loss did influence
final limb salvage. AGEs are associated with vessel wall changes and
have been associated with neuropathy, which may also be due to a
microangiopathy. Whether this is cause and effect or an association
remains to be determined, because the cause of the diabetic foot is
multifactorial, and limb loss is most often driven by superimposed
infections. We appreciate the authors’ thoughtful comments on
our article and their contribution to the further understanding of
the role of diabetes in the management of the patients with SFA
disease.
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Regarding “A randomized trial of carotid stenting
with and without cerebral protection”
Congratulations to the Journal of Vascular Surgery for publish-
ing the excellent, albeit small, article by Barbato JE, Dillavou E,
Horowitz MB, Jovin TG, Kant E, David S, and Makaroun MS. A
randomized trial of carotid stentingwith andwithout cerebral protec-
tion. J Vasc Surg 2008;47:760-5. Diffusion weighted magnetic reso-
nance imaging (MRI) has consistently demonstrated a high rate of
ipsilateral and contralateral infarction following carotid stenting.
Whether it is 40%1 or 70% as in the current study, it is an attention-
getting fact. Others have shown a lack of correlation between filter-
captured debris and the incidence of infarcts,2 quite possibly because
placement of the filter itself causes some embolization. For those who
defend carotid stents or filters, the best rebuttal to these datawould be
additional well controlled studies using MRI. So far, the incidence of
infarcts after CEA has been about one tenth that of stents with or
without filters. In the meantime, is it not appropriate to inform
patients that they are likely to have several small infarcts in their brain
when a stent is placed? How many surgeons would accept this for
themselves? The current article will surely have its highly motivated
detractors but these data argue well that carotid stents and filters
require further study through scientifically conducted, unbiased trials
that should include MRI as an endpoint.3
Frank W. LoGerfo, MD
Beth Israel Deaconess Medical Center
Boston, Mass
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Regarding “Multidisciplinary approach in the
management of a giant arteriovenous malformation in
the right axillary region”
In this article,1 the authors have made an excellent contribu-
tion to the contemporary management of the arteriovenous mal-
formation (AVM) lesion utilizing sound judgment and appropriate
decision making, addressing three critical issues.
First, they implemented a “multidisciplinary approach”2 to
evaluate and address a limb-threatening AVM lesion where an
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ill-planned surgical procedure had been previously attempted.
They did not explain how they made their decision.
In the last century, surgeons treated the congenital vascular
malformation (CVM) solely through a surgical approach. This
“cavalier approach,” with limited knowledge of the natural history
of these lesions, often resulted in extremely poor outcomes with
high morbidity and high rates of recurrence. Dismal outcomes
were due to the natural biologic behavior of the CVM lesion.
Surgeons later learned that the embryological characteristics of the
CVMs play a critical role in its behavior.
All CVM lesions derived from an “earlier” stage of embryo-
genesis maintain their mesenchymal cell characteristics, such that
they proliferate when stimulated by incomplete excision or simple
ligation of a feeding artery. These embryonic tissue remnants,
classified as “extratruncular” lesions, are often surgically inaccessi-
ble and difficult to remove completely. Therefore, only a carefully
planned multidisciplinary approach, combining both endovascular
therapy and open surgical treatment, is able to deliver a successful
outcome, as the authors demonstrated beautifully.
Second, the authors have made a critical decision to limit the
extent of the coil embolization therapy and stent grafting, and
utilized the endovascular therapy as a means to reduce the risk of
massive bleeding during the subsequent surgery. They did not rely
solely on an endovascular approach as an independent and perma-
nent treatment. Again, they did not explain their rational of this
approach.
Up until a few decades ago, simple ligation/ablation of a
feeding artery of an AVM lesion was often performed without
knowledge of the characteristics of extratruncular AVM lesions.
This maneuver deprives the AVM lesion of its arterial supply only
temporarily, which then ultimately stimulates this embryonic tissue
remnant with mesenchymal cell characteristics. The nidus of the
lesion will soon proliferate and develop new arterial collaterals via
“neovascular recruitment,” making the condition worse. There-
fore, ligation/ablation of the feeding artery as a sole, permanent
treatment should no longer be practiced as the authors wisely
demonstrated.
Third, the authors made another critical decision to perform
ethanol sclerotherapy3 prior to surgical excision. This was a wise
decision. As before, they did not explain clearly their rationale and
why they took this approach.
The only way to achieve a curative resection of an extratruncular
AVM lesion is to completely destroy the endothelial cells of the nidus
in order to prevent its recurrence. Ethanol is the only sclerotherapy
agent that has been shown to deliver permanent destruction of the
lesion nidus (with mesenchymal cell characteristics). Because this
extratruncular lesion is not a well localized one, but rather a diffusely
infiltrating lesion, preoperative embolization therapy with N-butyl
cyanoacrylate would not have been as good a choice as ethanol
sclerotherapy to deliver effective local control. Ethanol sclerotherapy
provided extra reassurance of permanent destruction of any potential
residual cells present following excision.
The authors have successfully utilized a multidisciplinary ap-
proach to the treatment of a high risk AVM lesion,4 combining
both endovascular therapies with open surgical resection, resulting
in an excellent outcome. We continue to support and promote this
multidisciplinary approach to the AVM.
Byung-Boong Lee, MD, PhD
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Reply
I appreciate your comments about my article1 entitled “Mul-
tidisciplinary approach in the management of a giant arteriovenous
malformation.”
The only reason I did not explain in detail why I chose the
multidisciplinary approach to treat this AVM (endovascular thera-
pies plus open surgical resection) was that I had to write the case
using only 350 words (as a Vascular Image). I agree with all your
comments, and I also think that the multidisciplinary approach is
the best strategy to treat these lesions.
Célio Teixeira Mendonça, MD, PhD
Positivo University
Curitiba, Brazil
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Regarding “Pharmacologic risk factor management in
peripheral arterial disease: A vade mecum for vascular
surgeons”
The excellent article by Rehring et al1 suggests specific recom-
mendations for tobacco cessation, blood pressure control, lipid-
lowering agents, and antiplatelet therapy in patients with periph-
eral arterial disease (PAD). A risk factor that perhaps deserves more
extensive discussion is the presence of diabetes mellitus (DM) in
these patients.
The authors mention that, “there are little data to support that
aggressive control of blood glucose levels improves risk of MI,
stroke, vascular death, or amputation.”1 The results of an earlier
study comparing the severity and outcome of PAD inDM (n 58)
and non-DM (n  68) patients may be of interest.2 This study
showed that during a follow-up period of 4.47  1.25 years for
DM vs 4.52  1.23 years for non-DM patients (P  .85), DM
patients were five times more likely than non-DM patients to
undergo an amputation (41.4% vs 11.5%), with an odds ratio (OR)
of 5.4 (95% confidence interval [CI], 2.3-12.9; P  .0001) and
three times more likely to die (51.7% vs 25.6%), with an OR of 3.1
(95% CI, 1.5-6.4; P  .002).2
As reported in a Consensus Statement of the American Dia-
betes Association, “the natural history of PAD in diabetic patients
has not specifically been studied longitudinally, but it is known
from prospective clinical trials of risk interventions that the cardio-
vascular event rates in patients with PAD and diabetes are higher
than those of their nondiabetic counterparts.”3 This can also be
extrapolated from the fact that “PAD is marker of systemic vascular
disease involving coronary, cerebral and renal vessels, leading to an
elevated risk of events, such as myocardial infarction, stroke, and
death.”3
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